Selva to Present Preclinical Data at ASV 2021 Demonstrating Prophylactic and Therapeutic Oral Dosing of SLV213 for COVID-19 Protected Lungs from SARS-CoV-2-Induced Damage

Excerpt from the Press Release:

SAN DIEGO–(BUSINESS WIRE)–Selva Therapeutics, Inc. (“Selva”) announced new preclinical data demonstrating SLV213, when given as a prophylactic or a treatment for SARS-CoV-2 infection, protects against SARS-CoV-2-induced diffuse alveolar damage (DAD), which is associated with the early stages of acute respiratory distress syndrome (ARDS). Additional in vitro data show that SLV213 greatly enhances the efficacy of remdesivir and molnupiravir, two drugs that target the virus. These data will be presented at the 40th Annual Meeting of the American Society of Virology (ASV) taking place virtually July 19-23.

“These preclinical data show that not only is SLV213 highly potent as a monotherapy before and after SARS-CoV-2 infection to potentially prevent severe COVID-19 and hospitalization but it also synergizes and complements the activity of remdesivir and molnupiravir,” said Ted Daley, CEO of Selva. “As one of the few, if not only, oral host-acting antivirals in development that can block viral entry and retain effectiveness against SARS-CoV-2 variants, we believe there is great urgency to advance SLV213 in clinical trials as a prophylactic and treatment for COVID-19 to prevent hospitalization and progression to severe disease.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release